Trastuzumab

monoclonal antibody

Identifier: CI-DRUG-00000605
Entity page: /drug/trastuzumab ↗
Edges: 1,080

Neighbours: 22 cancers1 genes12 variants10 trials15 approvals
Drawn: 60 of 60 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,149 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Trastuzumab approved for …APPROVED_FOR23 of 40show all (up to 200)
→ approved for	Gastroesophageal Junction Adenocarcinomasubtype 3 source records aggregated	supports	FDA ORIG	Gastroesophageal Junction Adenocarcinoma	3	Regulatory	openfda	graph →
→ approved for

→ approved for

EMA · EU · 2025Breast cancer Metastatic breast cancer Dazublys is indicated for the treatment of adult patients with HER2-positive metastatic breast cancer (MBC): as monotherapy for the treatment of those patients who have received at least two chemotherapy regimens for their metastatic disease. Prior chemotherapy must have included at least an anthracycline and a taxane unless patients are unsuitable for these treatments. Hormone receptor-positive patients must also have failed hormonal therapy unless patients are unsuitable for these treatments. in combination with paclitaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease and for whom an anthracycline is not suitable. in combination with docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease. in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor-positive MBC, not previously treated with trastuzumab. Early breast cancer Dazublys is indicated for the treatment of adult patients with HER2-positive early breast cancer. (EBC). following surgery, chemotherapy (neoadjuvant or adjuvant) and radiotherapy (if applicable) (see section 5.1). following adjuvant chemotherapy with doxorubicin and cyclophosphamide in combination with paclitaxel or docetaxel. in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin. in combination with neoadjuvant chemotherapy followed by adjuvant Dazublys therapy for locally advanced (including inflammatory) disease or tumors> 2 cm in diameter (see sections 4.4 and 5.1). Dazublys should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay (see sections 4.4 and 5.1). Metastatic gastric cancer Dazublys in combination with capecitabine or 5-fluorouracil and cisplatin is indicated for the treatment of adult patients with HER2 positive metastatic adenocarcinoma of the stomach or gastro-esophageal junction who have not received prior anti-cancer treatment for their metastatic disease. Dazublys should only be used in patients with metastatic gastric cancer (MGC) whose tumors have HER2 overexpression as defined by IHC2+ and a confirmatory SISH or FISH result or by an IHC 3+ result. Accurate and validated assay methods should be used (see sections 4.4 and 5.1).

EMA (EU) · approved · 2025-06-30 · Breast cancer Metastatic breast cancer Dazublys is indicated for the treatment of adult patients with HER2-positive metastatic breast cance…

—

approved

not mapped

Regulatory

ema

open ↗

→ approved for

EMA · EU · 2024Metastatic breast cancer (MBC) For the treatment of adult patients with HER2-positive MBC: as monotherapy for the treatment of those patients who have received at least two chemotherapy regimens for their metastatic disease. Prior chemotherapy must have included at least an anthracycline and a taxane unless patients are unsuitable for these treatments. Hormone receptor positive patients must also have failed hormonal therapy unless patients are unsuitable for these treatments. in combination with paclitaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease and for whom an anthracycline is not suitable in combination with docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive MBC, not previously treated with trastuzumab  Early breast cancer (EBC) For the treatment of adult patients with HER2-positive EBC: following surgery, chemotherapy (neoadjuvant or adjuvant) and radiotherapy (if applicable) following adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxel. in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin. in combination with neoadjuvant chemotherapy followed by adjuvant HD201 therapy, for locally advanced (including inflammatory) disease or tumours >2 cm in diameter.  HD201 should only be used in patients with MBC or EBC whose tumours have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay. Metastatic gastric cancer (MGC) In combination with capecitabine or 5-fluorouracil and cisplatin for the treatment of adult patients with HER2-positive metastatic adenocarcinoma of the stomach or gastroesophageal junction who have not received prior anti-cancer treatment for their metastatic disease. HD201 should only be used in patients with MGC whose tumours have HER2 overexpression as defined by Immunohistochemistry (IHC) 2+ and a confirmatory silver-enhanced in situ hybridisation (SISH) or fluorescence in situ hybridisation (FISH) result, or by an IHC 3+ result. Accurate and validated assay methods should be used.

EMA (EU) · approved · 2024-09-19 · Metastatic breast cancer (MBC) For the treatment of adult patients with HER2-positive MBC: as monotherapy for the treatment of those patien…

—

approved

not mapped

Regulatory

ema

open ↗

→ approved for

EMA · EU · 2020Breast cancer Metastatic breast cancer Zercepac is indicated for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC): as monotherapy for the treatment of those patients who have received at least two chemotherapy regimens for their metastatic disease. Prior chemotherapy must have included at least an anthracycline and a taxane unless patients are unsuitable for these treatments. Hormone receptor positive patients must also have failed hormonal therapy, unless patients are unsuitable for these treatments.                      in combination with paclitaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease and for whom an anthracycline is not suitable. in combination with docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease. in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive MBC, not previously treated with trastuzumab. Early breast cancer Zercepac is indicated for the treatment of adult patients with HER2 positive early breast cancer (EBC). following surgery, chemotherapy (neoadjuvant or adjuvant) and radiotherapy (if applicable). following adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxel. in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin. in combination with neoadjuvant chemotherapy followed by adjuvant Zercepac therapy, for locally advanced (including inflammatory) disease or tumours > 2 cm in diameter. Zercepac should only be used in patients with metastatic or early breast cancer whose tumours have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay. Metastatic gastric cancer Zercepac in combination with capecitabine or 5-fluorouracil and cisplatin is indicated for the treatment of adult patients with HER2 positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction who have not received prior anti-cancer treatment for their metastatic disease. Zercepac should only be used in patients with metastatic gastric cancer (MGC) whose tumours have HER2 overexpression as defined by IHC2+ and a confirmatory SISH or FISH result, or by an IHC 3+ result. Accurate and validated assay methods should be used.

EMA (EU) · approved · 2020-07-27 · Breast cancer Metastatic breast cancer Zercepac is indicated for the treatment of adult patients with HER2 positive metastatic breast cance…

—

approved

not mapped

Regulatory

ema

open ↗

Trastuzumab predicts response to …PREDICTS_RESPONSE_TO15 of 29show all (up to 200)
← predicts response to	ERBB2 Amplificationamplification 3 source records aggregated	sensitivity	A	Gastric Adenocarcinoma,HER2-Positive Breast Carcinoma	3	Curated	civic	graph →
← predicts response to	ERBB2 Amplificationamplification 19 source records aggregated	sensitivity	B	Bladder Carcinoma,Gastric Adenocarcinoma,HER2-Positive Breast Carcinoma+4	19	Curated	civic	graph →
← predicts response to	PTEN Lossdeletion_cna 5 source records aggregated	resistance	B	Gastric Adenocarcinoma,HER2-Positive Breast Carcinoma,Malignant Breast Neoplasm	5	Curated	civic	graph →
← predicts response to	PIK3CA Mutationother 3 source records aggregated	resistance	B	HER2-Positive Breast Carcinoma,Malignant Breast Neoplasm	3	Curated	civic	graph →
← predicts response to	ERBB2 MutationSNV	sensitivity	B	Lung Non-Small Cell Carcinoma	1	Curated	civic	graph →
← predicts response to	PTEN Expressionexpression	sensitivity	B	Malignant Breast Neoplasm	1	Curated	civic	graph →
← predicts response to	AKT2 EXPRESSIONexpression	sensitivity	B	Malignant Breast Neoplasm	1	Curated	civic	graph →
← predicts response to	BIRC5 Overexpressionexpression	resistance	B	HER2-Positive Breast Carcinoma	1	Curated	civic	graph →
← predicts response to	ERBB2 Amplificationamplification 4 source records aggregated	sensitivity	C	Cholangiocarcinoma,Endometrial Serous Adenocarcinoma,Lung Small Cell Carcinoma+1	4	Curated	civic	graph →
← predicts response to	ERBB2 Overexpressionexpression 2 source records aggregated	sensitivity	C	Malignant Salivary Gland Neoplasm	2	Curated	civic	graph →
← predicts response to	ERBB2 Kinase Domain Mutation	sensitivity	C	Lung Adenocarcinoma	1	Curated	civic	graph →
← predicts response to	PIK3CA E545KSNV 4 source records aggregated	resistance	D	HER2-Positive Breast Carcinoma	4	Curated	civic	graph →
← predicts response to	PIK3CA H1047RSNV 3 source records aggregated	resistance	D	HER2-Positive Breast Carcinoma	3	Curated	civic	graph →
← predicts response to	ERBB2 Amplificationamplification 3 source records aggregated	sensitivity	D	HER2-Positive Breast Carcinoma,Malignant Breast Neoplasm	3	Curated	civic	graph →
← predicts response to	PIK3CA C420RSNV	resistance	D	HER2-Positive Breast Carcinoma	1	Curated	civic	graph →

Trastuzumab targets …TARGETS1 of 1
→ targets	ERBB2	—	INHIBITOR	—	1	Curated	chembl	graph →

Trastuzumab investigated for …INVESTIGATED_FOR15 of 76show all (up to 200)
→ investigated for	HER2-Positive Breast Carcinomamolecular_subtype 2 source records aggregated	supports	A	HER2-Positive Breast Carcinoma	2	Curated	civic	graph →
→ investigated for	Gastric Adenocarcinomasubtype	supports	A	Gastric Adenocarcinoma	1	Curated	civic	graph →
→ investigated for	HER2-Positive Breast Carcinomamolecular_subtype 15 source records aggregated	supports	B	HER2-Positive Breast Carcinoma	15	Curated	civic	graph →
→ investigated for	Malignant Breast Neoplasmcancer_family 5 source records aggregated	supports	B	Malignant Breast Neoplasm	5	Curated	civic	graph →
→ investigated for	Malignant Colorectal Neoplasmsubtype 4 source records aggregated	supports	B	Malignant Colorectal Neoplasm	4	Curated	civic	graph →
→ investigated for	Gastric Adenocarcinomasubtype 2 source records aggregated	supports	B	Gastric Adenocarcinoma	2	Curated	civic	graph →
→ investigated for	Malignant Pancreatic Neoplasmcancer	supports	B	Malignant Pancreatic Neoplasm	1	Curated	civic	graph →
→ investigated for	Salivary Gland Carcinomasubtype	supports	B	Salivary Gland Carcinoma	1	Curated	civic	graph →
→ investigated for	Malignant Biliary Tract Neoplasmsubtype	supports	B	Malignant Biliary Tract Neoplasm	1	Curated	civic	graph →
→ investigated for	Lung Non-Small Cell Carcinomasubtype	supports	B	Lung Non-Small Cell Carcinoma	1	Curated	civic	graph →
→ investigated for	Bladder Carcinomasubtype	supports	B	Bladder Carcinoma	1	Curated	civic	graph →
→ investigated for	Gastric Neoplasmcancer_family	unknown	4	Gastric Neoplasm	1	Curated	chembl	graph →
→ investigated for	Neoplasmcancer_family	unknown	4	Neoplasm	1	Curated	chembl	graph →
→ investigated for	Breast Neoplasmcancer_family	unknown	4	Breast Neoplasm	1	Curated	chembl	graph →
→ investigated for	Malignant Salivary Gland Neoplasmcancer 2 source records aggregated	supports	C	Malignant Salivary Gland Neoplasm	2	Curated	civic	graph →

Trastuzumab investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 139show all (up to 200)
→ investigated in trials for	Malignant Breast Neoplasmcancer_family 442 trials (71 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Breast Neoplasm	442	Observed	clinicaltrials	graph →
→ investigated in trials for	HER2-Positive Breast Carcinomamolecular_subtype 115 trials (38 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	HER2-Positive Breast Carcinoma	115	Observed	clinicaltrials	graph →
→ investigated in trials for	Breast Neoplasmcancer_family 114 trials (25 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Breast Neoplasm	114	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Gastric Neoplasmcancer 45 trials (11 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Gastric Neoplasm	45	Observed	clinicaltrials	graph →
→ investigated in trials for	Breast Carcinoma 22 trials (3 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Breast Carcinoma	22	Observed	clinicaltrials	graph →
→ investigated in trials for	Solid Neoplasm 22 trials (8 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Solid Neoplasm	22	Observed	clinicaltrials	graph →
→ investigated in trials for	Gastric Neoplasmcancer_family 20 trials (7 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Gastric Neoplasm	20	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Neoplasm 19 trials (4 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Neoplasm	19	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Colorectal Neoplasmsubtype 15 trials (7 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Colorectal Neoplasm	15	Observed	clinicaltrials	graph →
→ investigated in trials for	HER2-Positive Gastric Adenocarcinoma 13 trials (8 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	HER2-Positive Gastric Adenocarcinoma	13	Observed	clinicaltrials	graph →
→ investigated in trials for	Gastroesophageal Junction Adenocarcinomasubtype 12 trials (5 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Gastroesophageal Junction Adenocarcinoma	12	Observed	clinicaltrials	graph →
→ investigated in trials for	Lung Non-Small Cell Carcinomasubtype 11 trials (3 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Lung Non-Small Cell Carcinoma	11	Observed	clinicaltrials	graph →
→ investigated in trials for	Male Breast Carcinoma 11 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Male Breast Carcinoma	11	Observed	clinicaltrials	graph →
→ investigated in trials for	Gastric Adenocarcinomasubtype 10 trials (7 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Gastric Adenocarcinoma	10	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Esophageal Neoplasm 10 trials (3 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Esophageal Neoplasm	10	Observed	clinicaltrials	graph →

Trastuzumab studied in …STUDIED_INderived10 of 795show all (up to 200)
→ studied in	NCT07007559Phase 2 · recruiting ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer · 795 trials list this drug (178 active)	—	—	Malignant Breast Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT00295893Phase 2 · active not recruiting Combination Chemotherapy With or Without Trastuzumab in Treating Patients With Stage II or Stage III Breast Cancer · 795 trials list this drug (178 active)	—	—	Malignant Breast Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT02390427Phase 1 · completed Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer · 795 trials list this drug (178 active)	—	—	Malignant Breast Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT03716180Phase 1 · active not recruiting DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC · 795 trials list this drug (178 active)	—	—	Malignant Breast Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT05152147Phase 3 · active not recruiting A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers · 795 trials list this drug (178 active)	—	—	Gastric Neoplasm,Esophageal Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06123338Phase 2 · recruiting A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer · 795 trials list this drug (178 active)	—	—	Malignant Esophageal Neoplasm,Gastric Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07407920Phase 2 · recruiting Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial · 795 trials list this drug (178 active)	—	—	Early Stage HER2-Positive Breast Carcinoma,Early Stage Triple-Negative Breast Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03367676Phase 2 · terminated 12 weekS Adjuvant dOcetaxel Plus trastuzumaB in Patients With Small, Node-negative, HER2-positive Breast cancER (SOBER) · 795 trials list this drug (178 active)	—	—	Malignant Breast Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT07315750Phase 3 · recruiting A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. · 795 trials list this drug (178 active)	—	—	Gastric Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07829900completed First-Line Dual Versus Single HER2-Targeted Therapy With Docetaxel for Advanced HER2-Positive Breast Cancer · 795 trials list this drug (178 active)	—	—	Malignant Breast Neoplasm,HER2-Positive Breast Carcinoma	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Paths